Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the u...
Saved in:
| Main Authors: | Aurélie Courtin, Frances M Richards, Tashinga E Bapiro, Jo L Bramhall, Albrecht Neesse, Natalie Cook, Ben-Fillippo Krippendorff, David A Tuveson, Duncan I Jodrell |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0067330&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.
by: Frances M Richards, et al.
Published: (2012-01-01) -
Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma
by: Jordan Powell, et al.
Published: (2025-04-01) -
Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer
by: Bi-Yang Cao, et al.
Published: (2025-03-01) -
Dietary silymarin supplementation enhances chemotherapy efficacy of capecitabine and irinotecan and mitigates hepatotoxicity in a mouse model of colon cancer
by: Sepideh Hassani, et al.
Published: (2025-01-01) -
Adherence and safety study in patients on treatment with capecitabine
by: Francisca Fernández-Ribeiro, et al.
Published: (2017-03-01)